MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting

MARIETTA, Ga., Feb. 1, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that they will be attending the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, February 15 – 19, 2011.  The meeting will be held at the San Diego Convention Center in San Diego, California.  

MiMedx reported that it will have a sizable presence at AAOS this year to present the potential  numerous trauma, sports medicine, spine and wound care applications that are being developed with the Company's three technologies, CollaFix™, HydroFix™ and its newest technology, AmnioFix™.   During the week of the conference, MiMedx plans to hold various meetings with physicians and scientists to demonstrate the benefits of its current and potential products and implants and share the progress being made in its CollaFix™ technology.

MiMedx recently acquired its AmnioFix™ technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion® process.

MiMedx Group will be located in Booth 5915 at the San Diego Conference Center.  

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  

SOURCE MiMedx Group, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED